About this item:

765 Views | 0 Downloads

Author Notes:

Correspondence: Dr. Lily Yang; Email: lyang02@emory.edu and Dr. Shuming Nie; Email: snie@emory.edu

Acknowledgments: We would like to thank Dr. Fred Miller for kindly providing us with 4T1 cell line, and Drs. Adam Marcus and Katherine Schafer-Hales in the Cell Imaging Core of the Winship Cancer Institute for their assistance with confocal microscopy.


Research Funding:

This research project is supported by the Emory-Georgia Tech Nanotechnology Center for Personalized and Predictive Oncology of NIH, the NCI Center of Cancer Nanotechnology Excellence (CCNE, U54 CA119338-01), and in part by the Idea Award of the Breast Cancer Research Program of the Department of Defense (BC 021952), a seed grant from the Golfers Against Cancer, and the Nancy Panoz Endowed Chair (Dr. Lily Yang).


  • antibodies
  • drug delivery
  • nanoparticles
  • proteins
  • quantum dots

Single Chain Epidermal Growth Factor Receptor Antibody Conjugated Nanoparticles for in vivo Tumor Targeting and Imaging

Show all authors Show less authors


Journal Title:



Volume 5, Number 2


, Pages 235-243

Type of Work:

Article | Post-print: After Peer Review


Epidermal growth factor receptor (EGFR) targeted nanoparticle are developed by conjugating a single-chain anti-EGFR antibody (ScFvEGFR) to surface functionalized quantum dots (QDs) or magnetic iron oxide (IO) nanoparticles. The results show that ScFvEGFR can be successfully conjugated to the nanoparticles, resulting in compact ScFvEGFR nanoparticles that specifically bind to and are internalized by EGFR-expressing cancer cells, thereby producing a fluorescent signal or magnetic resonance imaging (MRI) contrast. In vivo tumor targeting and uptake of the nanoparticles in human cancer cells is demonstrated after systemic delivery of ScFvEGFR-QDs or ScFvEGFR-IO nanoparticles into an orthotopic pancreatic cancer model. Therefore, ScFvEGFR nanoparticles have potential to be used as a molecular-targeted in vivo tumor imaging agent. Efficient internalization of ScFvEGFR nanoparticles into tumor cells after systemic delivery suggests that the EGFR-targeted nanoparticles can also be used for the targeted delivery of therapeutic agents.

Copyright information:

© 2009 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim

Export to EndNote